Your browser doesn't support javascript.
loading
Implementable assay for monitoring minimum residual disease after radical treatment for colorectal cancer.
Nakano, Takafumi; Takao, Seiichiro; Dairaku, Katsushi; Uno, Naoki; Low, Siew-Kee Amanda; Hashimoto, Masahiro; Tsuda, Yasuo; Hisamatsu, Yuichi; Toshima, Takeo; Yonemura, Yusuke; Masuda, Takaaki; Eto, Ken; Ikegami, Toru; Fukunaga, Yosuke; Niida, Atsushi; Nagayama, Satoshi; Mimori, Koshi.
Afiliação
  • Nakano T; Department of Surgery, Kyushu University Beppu Hospital, Beppu, Japan.
  • Takao S; Department of Surgery, The Jikei University School of Medicine, Tokyo, Japan.
  • Dairaku K; Department of Surgery, Kyushu University Beppu Hospital, Beppu, Japan.
  • Uno N; Department of Clinical Radiology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
  • Low SA; Department of Surgery, Kyushu University Beppu Hospital, Beppu, Japan.
  • Hashimoto M; Department of Surgery, The Jikei University School of Medicine, Tokyo, Japan.
  • Tsuda Y; Department of Laboratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
  • Hisamatsu Y; Department of Colorectal Surgery, Gastroenterological Cancer Center, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Toshima T; Department of Surgery, Kyushu University Beppu Hospital, Beppu, Japan.
  • Yonemura Y; Department of Surgery, Kyushu University Beppu Hospital, Beppu, Japan.
  • Masuda T; Department of Surgery, Kyushu University Beppu Hospital, Beppu, Japan.
  • Eto K; Department of Surgery, Kyushu University Beppu Hospital, Beppu, Japan.
  • Ikegami T; Department of Surgery, Kyushu University Beppu Hospital, Beppu, Japan.
  • Fukunaga Y; Department of Surgery, Kyushu University Beppu Hospital, Beppu, Japan.
  • Niida A; Department of Surgery, The Jikei University School of Medicine, Tokyo, Japan.
  • Nagayama S; Department of Surgery, The Jikei University School of Medicine, Tokyo, Japan.
  • Mimori K; Department of Colorectal Surgery, Gastroenterological Cancer Center, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
Cancer Sci ; 115(6): 1989-2001, 2024 Jun.
Article em En | MEDLINE | ID: mdl-38531808
ABSTRACT
Considering the cost and invasiveness of monitoring postoperative minimal residual disease (MRD) of colorectal cancer (CRC) after adjuvant chemoradiotherapy (ACT), we developed a favorable approach based on methylated circulating tumor DNA to detect MRD after radical resection. Analyzing the public database, we identified the methylated promoter regions of the genes FGD5, GPC6, and MSC. Using digital polymerase chain reaction (dPCR), we termed the "amplicon of methylated sites using a specific enzyme" assay as "AMUSE." We examined 180 and 114 pre- and postoperative serial plasma samples from 28 recurrent and 19 recurrence-free pathological stage III CRC patients, respectively. The results showed 22 AMUSE-positive of 28 recurrent patients (sensitivity, 78.6%) and 17 AMUSE-negative of 19 recurrence-free patients (specificity, 89.5%). AMUSE predicted recurrence 208 days before conventional diagnosis using radiological imaging. Regarding ACT evaluation by the reactive response, 19 AMUSE-positive patients during their second or third blood samples showed a significantly poorer prognosis than the other patients (p = 9E-04). The AMUSE assay stratified four groups by the altered patterns of tumor burden postoperatively. Interestingly, only 34.8% of cases tested AMUSE-negative during ACT treatment, indicating eligibility for ACT. The AMUSE assay addresses the clinical need for accurate MRD monitoring with universal applicability, minimal invasiveness, and cost-effectiveness, thereby enabling the timely detection of recurrences. This assay can effectively evaluate the efficacy of ACT in patients with stage III CRC following curative resection. Our study strongly recommends reevaluating the clinical application of ACT using the AMUSE assay.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Colorretais / Neoplasia Residual / Recidiva Local de Neoplasia Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Cancer Sci Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Japão

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Colorretais / Neoplasia Residual / Recidiva Local de Neoplasia Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Cancer Sci Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Japão